Abstract 723
Background
Only few studies on limited series of patients have evaluated the efficacy of immunotherapy in patients with metastatic mucosal melanoma (MM) or uveal melanoma (UM). The aim of the study was to assess the objective response rate and survival of patients with metastatic MM or UM treated with anti-CTLA-4 or anti-PD-1.
Methods
A multicenter retrospective study was performed in 25 Dermatology Departments in France. All patients with stage IIIC to IV MM or UM who were treated with anti-CTLA-4 or anti-PD-1 between 2008 and 2016 were included. Tumor response was evaluated according to RECISTv1.1 criteria at Week 12, and compared with a second cohort of patients treated with chemotherapy from 2000 to 2016. Overall survival (OS) was evaluated using Kaplan Meier method, and adjusted for main prognostic factors. UM or MM were analysed separately.
Results
A total of 439 patients were included, 229 with MM (151 treated with immunotherapy and 78 treated with chemotherapy) and 210 with UM (100 treated with immunotherapy and 110 treated with chemotherapy). Objective response rates of MM to anti-CTLA-4 and anti-PD-1 were 3/76 (3.9%, 95%CI=0.5%-8.3%) and 15/75 (20%, 95%CI=0.9%-29.1%) respectively, versus 11/78 (14.1%, 95%CI=6.4%-21.8%) in patients treated with chemotherapy (p = 0.047 and p = 0.4). No tumor response was observed in UM patients treated with immunotherapy, versus 4/110 responses (3.6%, 95%CI=0.2-7.4%) in patients treated with chemotherapy (p = 0.12). The OS of MM patients treated with immunotherapy was longer than that of patients treated with chemotherapy (p = 0.002), with a median OS of 15.97 [interquartile range (IQR)=6.89-27.12] and 8.82 months [IQR=5.2-14.9], respectively. After adjusting for main prognostic factors, the OS of MM patients treated with immunotherapy remained longer than that of patients treated with chemotherapy (HR = 0.61 [0.4; 0.95], p = 0.028). The adjusted and non-adjusted OS of UM patients treated with immunotherapy was not different from that of patients treated with chemotherapy (HR = 1.06 [0.70; 1.61], p = 0.78) with median of 13.38 months [IQR=6.03-29.57] and 11.02 months [IQR=5.8-23.9], respectively.
Conclusions
Anti-PD-1 should be considered for the treatment of patients with advanced MM. The prognosis of metastatic UM remains poor.
Clinical trial identification
Legal entity responsible for the study
P. Joly.
Funding
Bristol-Myers Squibb.
Editorial Acknowledgement
Disclosure
N. Meyer: Consultant or investigator: BMS, MSD, Roche, GSK, Novartis, Amgen, Pierre Fabre. N. Beneton Benhard: Consultant: BMS, Novartis, Roche. J.-P. Arnault: Grant support for Congress: BMS, MSD; Investigator: Novartis. P. Joly: Consultant: BMS. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract